Reasons to publish


Rapid peer review and publication

Endocrine Oncology aims to return a decision on a peer-reviewed paper in less than a month. Accepted manuscripts are published online and fully citable within 24 hours of acceptance. Furthermore, articles are published continuously online as soon as the version of record is available i.e. just weeks from acceptance.


Publish free of charge

Bioscientifica is sponsoring the Article Publication Charge during the launch years, offering authors far-reaching exposure and impact for their work at no additional cost.*

There are also no colour costs charged when publishing in Endocrine Oncology

*Bioscientifica reserves the right to withdraw this offer at any time.


Maximise the reach of your work

Endocrine Oncology is a fully open-access, peer-reviewed journal brought to you by the Society for Endocrinology and Bioscientifica, a long-established society publisher.

Where appropriate, published articles are promoted to scientists and clinicians from all over the world to ensure maximum reach and visibility of our authors’ work.

How we may promote your work

  • Press releases for papers of high interest and broad appeal.
  • Communications and adverts to society memberships or in relevant publications.
  • Bioscientifica journals are promoted globally at conferences throughout the year and your article may be picked to feature on our handouts.
  • Email newsletters, including topic collections, sent to authors, readers, editors, reviewers and anybody else with an interest in the journal.
  • Social Media coverage.

Tips for promoting your own work

Get the most out of your published article by considering the following:

  • You will receive a link to your published article which you can send to colleagues who may be interested in your line of research.
  • Add your article to the list of publications on your institution’s webpages.
  • Use of social media: tweet your article and mention @EndoOncology for a retweet.
  • Link to the paper in work-related blogs and professional websites.
  • Finally, remember that your work is published open access and is free to read by anyone that may be interested!


Monitor the impact of your work with article-level metrics

Article-level metrics are available for articles published in Endocrine Oncology. This feature provides traditional usage data (number of article downloads/views) as well as Altmetric data for individual articles published in the journal. Altmetric provide non-traditional data by tracking a selection of online indicators (both scholarly and non-scholarly) to give a measurement of digital impact and reach. This information is used to generate an article’s Altmetric Attention Score.

These article-level metrics allow authors to monitor the impact of their research in academia and beyond.


Author experience

Bioscientifica Publishing prides itself on the provision of a personalised author service, and editorial office staff are on hand to offer assistance from submission through to publication. All authors are given the opportunity to provide feedback via an online survey, and in 2021, 60% of respondents indicated that their experience of publishing with Bioscientifica was better or much better than with other journal publishers**.

**Based on 464 respondents.



Addressing Impact Factor


As a new publication, Endocrine Oncology does not yet have an impact factor and the journal will apply for indexing in Journal Citation Reports (Science Citation Index Expanded) in due course. Although we appreciate that many researchers are under pressure from their funders and institutions to publish in high impact journals, the impact factor should not be considered the only measure of a journal or its content.

Where journals already possess a high impact factor and wish to maintain their citation count, articles can be prioritised based on the number of citations and broad impact they are likely to make on the field, rather than the quality of the work itself. This can lead to high-quality research from more niche areas of interest facing rejection. In this way impact factor is not necessarily an indication of quality and can be misleading when deciding where to publish your work.

The Endocrine Oncology Editorial Board will consider each submission on its own merit, placing emphasis on the quality of the research rather than the potential for broad impact on the field. After all, a data set which is particularly meaningful to researchers who work in a relatively small field will not attract high numbers of citations, however this does not mean that the work is not worthy of publication. Such an article might be considered low priority by a high impact journal, whereas its value would be much more recognised by the Endocrine Oncology Editorial Board.

The Editorial Board also pride themselves on high-standards of peer review, with Associate Editors aiming to obtain at least two reports from external reviewers before returning a publication decision to authors. This ensures that any work published is of the highest possible standard.

In addition to this, we also offer a breakdown of article-level metrics (abstract and full-text views, and pdf downloads) and Altmetrics, which help authors to track the success and impact of their publications in lieu of an impact factor.

If you would like to find out more about submitting your work to Endocrine Oncology, please read our Author Guidelines.